This study uses data from annual financial reports to compare the profitability of large pharmaceutical companies vs other large companies in the S&P 500 Index from 2000 to 2018, measured via gross profit; earnings before interest, taxes, depreciation, and amortization; and net income (earnings).
This study uses publicly available data to analyze research and development spending to win FDA approval and bring new drugs to market between 2009 and 2018.
This study describes changes in list prices, net prices, and discounts for branded pharmaceutical products in the US between 2007 and 2018 and estimates the extent to which list price increases were offset by increases in discounts.
This study estimates health care spending for the most common health conditions in the United States, including low back pain and musculoskeletal disorders, diabetes, and ischemic heart disease, between 1996 and 2016.
This study characterizes government, academia, and private funding for gene therapy trials in the United States by technology type and therapeutic and disease area.
This Viewpoint discusses underlying causes of generic drug shortages in the United States and proposes solutions to address those shortages, including financial incentives for manufacturers that provide a steady supply of high-quality products.
This Viewpoint considers the lawsuit United States v Gilead Sciences in the context of intellectual property rights and the patents held on medications for preexposure prophylaxis (PrEP) for HIV infection, leading to a trade-off between affordability and future pharmaceutical collaboration and innovation.
This Viewpoint characterizes reasons for the lack of evidence about the health effects of probiotic supplements and cautions against a “can’t hurt, can’t help” presumption made by consumers and clinicians.
In this narrative medicine essay, a 35-year-old psychiatrist reflects on his dreams in childhood, as an academic, and as a parent of a young child as he faces his own mortality.
This JAMA Guidelines Synopsis summarizes the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) 2019 recommendations on diagnosis and treatment of adults with community-acquired pneumonia.
This Medical Letter review summarizes evidence underlying American Thoracic Society and Infectious Diseases Society of America guideline recommendations on the use of corticosteroids as an adjunct to antimicrobials for the treatment of community-acquired pneumonia
This Medical News story examines the role of rebates in drug pricing.
This JAMA Patient Page discusses the issue of surprise medical bills and what steps patients can take to protect themselves from receiving them.
Create a personal account or sign in to: